Clinical Application of Inhibitors of Fibrinolysis

Drugs

Volumn 29, Issue 3, 1985, Pages 236-261

  Verstraete, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOMETHYLBENZOIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CAPTOPRIL; HEPARIN; PLASMINOGEN; STREPTOKINASE; SUXAMETHONIUM; TRANEXAMIC ACID; TUBOCURARINE CHLORIDE; UROKINASE;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; BLEEDING; BLOOD AND HEMOPOIETIC SYSTEM; BRAIN ISCHEMIA; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DIARRHEA; DRUG THERAPY; EXTRACORPOREAL CIRCULATION; FEMALE GENITAL SYSTEM; FIBRINOLYSIS; HEART; HEART INFARCTION; HEMOPHILIA; HEMORRHAGIC SHOCK; HUMAN; HYPERMENORRHEA; INTRAUTERINE CONTRACEPTIVE DEVICE; NAUSEA; PERIPHERAL VASCULAR SYSTEM; PHARMACOKINETICS; PREVENTION; PRIORITY JOURNAL; REVIEW; SUBARACHNOID HEMORRHAGE; THERAPY; VASOCONSTRICTION;

4-AMINOBENZOIC ACID; 6-AMINOCAPROIC ACID; ANGIONEUROTIC EDEMA; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD PRESERVATION; CORNEAL DISEASES; DRUG INTERACTIONS; EPISTAXIS; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMAN; INTRAUTERINE DEVICES; KINETICS; MALE; MYOCARDIAL INFARCTION; OVARIAN NEOPLASMS; PANCREATITIS; POSTOPERATIVE COMPLICATIONS; SHOCK; THROMBOPHLEBITIS; TRANEXAMIC ACID; TRYPSIN INHIBITORS;

EID: 0021954364     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198529030-00003     Document Type: Review

References (239)

1. Diffusion of tranexamic acid to the joint
2. Effect of antifibrinolytic agents and estrogens on blood loss and blood coagulation factors during open heart surgery
3. Inhibition of fibrinolytic and thromboplastic activity by Trasylol
4. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases
5. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA
6. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid
7. Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation
8. Arrest of growth of ovarian tumor by tranexamic acid
9. Recurrent abruptio placentae with the fibrinolytic inhibitor tranexamic acid
10. Influence of plasma protease inhibitors and Trasylol on trypsin-induced brady-kinin-release in vitro and in vivo
11. Demonstration of pancreatic protease-antiprotease complexes in the peritoneal fluid of patients with acute pancreatitis
12. Cimetidine and tranexamic acid in the treatment of acute uppergastrointestinal tract bleeding
13. Frühdiagnose und Therapie der Aneurysmablutungen
14. Subarachnoid haemorrhage
15. Antifibrinolytic treatment in haemophilia: A controlled trial of prophylaxis with tranexamic acid
16. Clot-selective coronary thrombolysis with tissue-type plasminogen activator
17. Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage
18. Tranexamic acid and upper gastrointestinal haemorrhage. A double blind trial
19. Acute renal failure and myopalhy after treatment with aminocaproic acid
20. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study
21. Action of a protcolytic enzyme inhibitor on blood coagulation in vitro
22. Fibrin adhesive: An important hemostatic adjunct in cardiovascular operations
23. Traumatic hyphaema treated with the antifibrinolytic drug tranexamic acid. I
24. Traumatic hyphaema treated with the antifibrinolytic drug tranexamic acid. II
25. A double-blind study on the influence of central corneal thickness after trabeculectomy for glaucoma simplex
26. A double-blind study of the influence of tranexamic acid on the central corneal thickness after cataract extraction
27. Bullous keratopathy (Fuchs’ endothelial dystrophy) treated systematically with 4-trans-aminocyclohexano-carboxylic acid
28. 2-plasmin inhibitor and C1-inactivator by human polymorphonudear leukocyte elastase
29. Development and evaluation of an inhibitorreleasing matrix for intrauterine devices
30. Treatment of menorrhagia with tranexamic acid. A double blind trial
31. Der Erfolg einer antifibrinolytischen Behandlung mit Tranexamsaure zur Reduktion der Blutverlustes während und nach Tonsillektomien
32. Effect of the kallikrein inhibitor aprotinin on myocardial ischemia and necrosis in man
33. Purpuric rash due to epsilonaminocaproic acid
34. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: A double blind clinical trial
35. Possible interaction between muscle relaxants and the kallikrein-trypsin inactivator ‘Trasylol’. Report of three cases
36. On the regulation and control of fibrinolysis
37. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of thrombus and route of administration
38. Tranexamic acid in upper gastrointestinal haemorrhage
39. Gastric fibrinolysis — a possible aetiological link with peptic ulcer
40. Evidence for the release of gastric fibrinolytic activity into peripheral blood
41. Tranexamic acid and arterial thrombosis
42. The neutralisation of heparin by Trasylol
43. Beeinflussung des Kininogen-Kininsystems durch einen Kallikreinhemmer bei Operationen am offenen Herzen in extracorporaler Zirkulation
44. Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog
45. Neue Aspekte zur durchblutungssteigernden und insulinähnlichen Wirkung der Muskelarbeit: Mögliche Beteiligund des Kallikrein-Kinin-Prostaglandin Systems
46. Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during muscular work
47. Influence of aprotinin (Trasylol) on the action of suxamethonium
48. Amino methyl cyclohexane carboxylic acid (AMCHA), A new synthetic fibrinolytic inhibitor
49. Some properties of the antifibrinolytically active isomer of amino-methylcyclohexanocarboxylic acid
50. Verminderung des postischämischen Extremitätenödems an der Ratte durch einen Proteinasenhemmer
51. Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract. A double-blind study
52. Hemophilia and dental treatment
53. Fibrinolytic mechanisms and the development of thrombolytic therapy
54. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms
55. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid haemorrhage: A consecutive controlled trial
56. Thranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease
57. Serial use of aprotinin and incidence of allergic reactions
58. Verteilung und Ausscheidung von natürlich vorkommenden und chemisch modifizierten Proteinaseninhibitoren nach intravenöser Injektion bei Ratte, Hund (und Mensch)
59. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs
60. Experimentelle Untersuchungen über den Einfluss des Ferment-Inhibitors Trasylol bei der Blutkonservierung
61. Haemostasis during transverical prostatic adenectomy
62. 2-macroglobulin complex by the protease inhibitor from bovine lung
63. Erfahrungen mit einem humanen Fibrinkleber bei operativen Eingriffen im Kopf-Hals-Bereich
64. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid
65. Le traitement des saignements dus aux stérilets par un inhibiteur de protéinases
66. Problems in hemostasis with extracorporeal apparatus
67. Akute Blutgerinnungsstörungen in der Geburtshilfe
68. Pathomechanismen und Klinik der Fruchtwasserembolie
69. The role of antifibrinolytic therapy in the preooperative management of recently ruptured intracranial aneurysms
70. Menstrual blood-loss with intrauterine devices
71. Pharmakologische Beeinflussung der thrombozytären Aggregatbildung und Freisetzungsreaktion in lagerndem Vollblut
72. Platelet function and proteinase inhibition
73. Beeinflussung der Thrombozytenfunktion und der Gerinnung von Konservenblut durch Azetylsalizylsäure und Aprotinin
74. Use of kallikrein and Trasylol in experimental animals
75. The role of kininogenases, kinin formation and kininogenase inhibition in post traumatic shock and related conditions
76. Trasylol in der Schocktherapie–Wirkung und Interpretation
77. A rationale for the therapeutic action of aprotinin
78. Trasylol, ein Proteinaseninhibitor bei chirurgischen und internen Indikationen
79. Das Verhalten des Trasylol im Organismus als Modell Für die Pharmakokinetik basischer Polypeptide
80. Aprotinin bei Operationen am offenen Herzen
81. Menstrual blood loss — a population study
82. Beeinflussung der Mikroaggregation in lagernden Blutkonserven
83. Aprotinin-ACD-Blut: Experimentelle Untersuchungen über den Einfluss von Aprotinin auf die plasmatische und thrombozytäre Gerinnung
84. Abdichtung poröser Gefassprothesen unter Teil-Heparinisierung und extrakorporaler Zirkulation
85. Antifibrinolytic therapy with Cyclokapron in connection with prostatectomy
86. Funktionelle Morphologie von Endstrombahn und Transitstrecke: Probleme beim Schock
87. Behandlung des polytraumatischen Schocks
88. Cerebral thrombosis associated with Amicar
89. Tranexamic acid therapy in ulcerative colitis
90. Trasylol in myocardial infarction
91. Studies on the mechanism of antifibrinolytic action of tranexamic acid
92. A single centre double blind trial of Trasylol therapy in primary acute pancreatitis
93. Tranexamic acid (AMCA) and late hyphaema. A double-blind study in cataract surgery
94. An enzymatic assay convenient for the control of aprotinin levels during proteinase inhibitor therapy
95. Epidemiology and course of gastrointestinal haemorrhage in Northeast Scotland
96. Enterale Resorption, Verteilung and Elimination von 4-aminomethylcyclohexancarbonsäure (AMCHA) und ∈-aminocapronsäure (EACS) beim Menschen
97. Die Wirkung von Trasylol auf verschiedene Ödemformen der Rattenpfote
98. Pharmacokinetic observations following intravenous administration of radioactive labelled aprotinin in volunteers
99. Secondary haemorrhage following traumatic hyphaema. A comparative study of conservative and tranexamic treatment
100. Interaction of the clotting, kininforming, complement and fibrinolytic pathways in inflammation
101. Plasminogen activators in the endometrium of women using intrauterine contraceptive devices
102. Tranexamic acid in subarachnoid hemorrhage. A double-blind study
103. Medikamentöse Genkung postoperatiever Blutungen nach Prostatiktomien
104. Zur Wirkung des natürlichen Proteinaseninhibitors Aprotinin auf die Plättchenfunktion beim alloarthroplastischen Hüftgelenkersatz
105. Wirkung von Aprotinin auf die Thrombozytenfunktion während Hüft-Totalendoprothesenoperationen
106. Konisation vid cancer in situ
107. Zur partiellen Klebung von Mikrogefässanastomosen im intrakraniellen Bereich
108. Tissue fibrinolysis in the digestive mucosa. III. Treatment of ulcerative colitis by the direct administration of an antifibrinolytic agent as an enema
109. Antifibrinolytic therapy of giant hypertrophie gastritis (Menetrier’s disease)
110. Untersuchungen der Blutgerinnungsveränderungen während und nach Operationen mit Hilfe der Herz-Lungen-Maschine
111. Über die Beeinflussung des Blutverlustes nach Prostataoperationen durch prä-operative Applikation von Antifibrinolytika
112. Le mode d’action des inhibiteurs de protéinases (Trasylol) dans les hémorragies intra-cräniennes
113. Effects of aprotinin on renal function and urinary prostaglandin excretion in conscious rats after acute salt loading
114. Über die Inaktivierung des Kallikreins
115. Human placental transfer of an antifibrinolytic agent (AMCA)
116. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor trypsin compound
117. Tissue repair in presence of locally applied inhibitors of fibrinolysis
118. Fibrinolytic activity in the normal and inflamed rectal mucosa
119. Late bleeding after conization. The effect of tranexamic acid (Cyclokapron)
120. Increased fibrinolytic activity in the endometrium of patients using copped IUD (Gravigard)
121. Influence of plasma proteinase inhibitors and aprotinin on trypsin-induced bradykinin release in vitro in man
122. An in vitro study of the influence of plasma protease inhibitors and aprotinin on trypsin-induced C3 cleavage in human serum
123. Tranexamic acid (Cyclokapron) in chronic urticaria: A double-blind study
124. Mechanism of association with trypsin (or chymotrypsin) with pancreatic trypsin inhibitor (Kunitz and Rajal) kinetics and thermodynamics of the inter-reaction
125. Protective effect of protease inhibition in myocardial ischemia
126. Die Beeinflussung der Fibrinolyse am traumatisierten Rattenhirn durch lokale Applikation von Aprotinin
127. Effects of epsilon-aminocaproic acid on coagulation and fibrinolytic mechanisms
128. Trasylol for pancreatitis (Correspondence)
129. Passage of tranexamic acid (AMCA) to semen in man and its effect on the fibrinolytic activity and in migration of spermatozoa
130. Über neue Hemmstoffe der Fibrinolyse
131. Is there a rationale for using a proteinase inhibitor as a standard additive to stored blood?
132. Natural proteinase inhibitors in extracorporeal circulation
133. Trasylol e blocco neuromuscolare
134. Synthetic inhibitors of fibrinolysis
135. Über das Stoffwechselschicksal der p-Aminomethylbenzosäure (PAMBA) beim Menshcen
136. The influence of drugs on disseminated intravascular coagulation (DIC). I. Effects of antifibrinolytics and fibrinolytics on thrombin-induced DIC in rats
137. Agrégation in vitro des plaquettes de rat par doses cumulées d’ADP: Influence de trois antiagrégants et d’un inhibiteur protéasique, l’aprotinine
138. Prolonged antifibrinolysis: An effective non-surgical treatment for ruptured intracranial aneurysms?
139. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: A clinial study
140. The absorption, distribution and excretion of epsilon-amino-caproic acid following oral or intravenous administration to man
141. Trasylol and failure of hemostasis
142. Morbidity of acute pancreatitis; the effect of aprotinin and glucagon
143. Biochemistry and toxicology of Amikapron: The antifibrinolytic active isomer of AMCHA
144. The prevention of secondary haemorrhage after prostatectomy: The value of antifibrinolytic therapy
145. The value of tranexamic acid (Cyclokapron) in the prevention of secondary bleeding, a complication of traumatic hyphaema
146. Evaluation of the safety of tranexamic acid. Teratogenic effects in mice and rats
147. Epsilon aminocaproic acid therapy in ulcerative colitis
148. Can excessive perioperative bleeding in cardiac surgery be reduced by means of an early treatment with either aprotinin or a new C1-protease-inhibitor?
149. Thrombotic state after hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid
150. Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in openheart surgery
151. Pharmacokinetics on blood concentration of aprotinin (Trasylol) in humans
152. Inhibitory effect of aprotinin and gabexate mesilate on human plasma kallikrein
153. Cooperative aneurysm study: Antihypertensive and antifibrinolytic therapy following subarachnoid haemorrhage from ruptured intracranial aneurysm
154. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). A double blind investigation
155. Treatment of menorrhagia
156. Fruchtwasserembolie mit Gerinnungsstörung ein kasuistischer Beitrag
157. Rational approach to proteinase inhibitors
158. Synthetic inhibitors of fibrinolysis: In vitro and in vivo mode of action
159. An active stereo isomer (trans form) of AMCHA and its fibrinolytic (antiplasminic) action in vitro and in vivo
160. Influence of tranexamic acid and acetylsalicylic acid on the thickness of the normal cornea
161. Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition
162. Interactions of diuretics with the renal kallikreinkinin and prostaglandin systems
163. Intraocular haemorrhages: A haemostatic therapeutic approach
164. Circulatory changes in the area of the lower extremities secondary to inactivity and the influence exerted on them by Trasylol
165. A double-blind study to evaluate the effect of epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (cyclokapron)
166. Proteinasenblockade bei abgestorbener Schwangerschaft, “dead fetus syndrome”
167. Calculations and hypothetical considerations on the inhibition of plasmin and plasma kallikrein by Trasylol
168. Pharmacokinetics and bioavailability of tranexamic acid
169. Studies on the cause of bleeding during and after surgery with a heart-lung machine in children with cyanotic and acyanotic congential cardiac defects and their prophylactic treatment
170. Studies on the anticoagulant action of aprotinin (Trasylol)
171. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia
172. Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial bleeding
173. Tooth extraction in hemophiliacs
174. Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets
175. Der Einfluss von Trasylol auf Plättchenaggregation, Plättchenretention und Plättchenfaktor-3-Verfügbarkeit
176. The effect of aprotinin on platelet counts and functions in the course of open heart surgery
177. Antifibrinolytic treatment with tranexamic acid (AMCHA) in Pediatric urinary tract surgery
178. Plasminogen activators in the endometrium II. Clinical aspects
179. The effect of tranexamic acid (AMCA) on postoperative bleeding after conization
180. Tranexamic acid and intracranial thrombosis
181. Fibrinolyse und Blutverlust nach Prostata-Operationen und deren Beeinflussbarkeit durch Antifibrinolytika
182. Results of a field study on the therapeutic value of aprotinin in traumatic shock
183. Pathological fibrinolysis
184. Tranexamic acid therapy in hereditary angioneurotoic edema
185. Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia
186. Mutagenicity studies of tranexamic acid
187. Alipathic amino compounds as inhibitors of plasminogen activation
188. Arteriopathic complications during treatment of subarachnoid haemorrhage with epsilonaminocaproic acid
189. Synthetische Inhibitoren des Thrombosis und andere Gerinnungsenzyme. Struktur and Wirkung
190. Additive protection of aprotinin, protease inhibitor to cold cardioplegia from ischemie myocardium
191. Abruptio placentae. Treatment with the fibrinolytic inhibitor tranexamic acid
192. Uterine Blutungen bei intrauteriner Kontrazeption
193. Intrauterine contraception and its side effects: Effects of local proteinase inhibition
194. Hemorrhage induced by intrauterine devices: Control by local proteinase inhibition
195. Epsilon-aminocaproic acid in the treatment of hemophilia and Christmas disease with special reference to the extraction of teeth
196. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega amino-carboxylic acids
197. The inhibition by Trasylol of fibrinolytic activity associated with cardiovascular operations
198. The ability of tranexamic acid to cross the blood-brain barrier and diffuse in patients with ruptured intracranial aneurysms
199. A controlled trial of Trasylol in the treatment of acute pancreatitis
200. Shock prevention studies. Hemodynamic measurements after administration of aprotinin and/or heparin during pancreatic cell autotransplantation in the dog, pig and monkey
201. Biochemie natürlicher Proteinase-Inhibitoren
202. Aprotinin for intraoperative haemostasis
203. Tranexamic acid in the prevention of secondary haemorrhage after traumatic hyphaema
204. Coronary thrombolysis in dogs with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology
205. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction
206. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: A double-blind controlled cllinicaJ trial
207. The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema
208. Effect of aprotinin-induced kallikrcin inhibition on the cardiovascular and renal action of captopril in diuretic-treated dogs
209. Antifibrinolytic treatment in subarachnoid hemorrhage
210. Antifibrinolytic treatment in subarachoid hemorrhage
211. A double-blind study of the effect of tranexamic acid in essential menorrhagia
212. Double-blind trials with ethamsylate, batroxobin or tranexamic acid on blood loss after adenotonsillectomy
213. Wound healing following dental extraction in rabbits: Effects of tranexamic acid, warfarin anticoagulation, and socket packing
214. Effects of tranexamic acid in the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding
215. Renal damage in post-pancreatitic shock and its therapeutic management. Experimental and clinical pathologico-anatomic findings
216. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator
217. Contribution to the biochemistry of Trasylol
218. Trasylol: A short survey on its history, biochemistry and activities
219. Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices
220. Effect of the protease inhibitor Trasylol in acute coronary occlusion in dogs
221. 2-antiplasmin
222. On the kinetics of the reaction between antiplasmin and plasmin
223. Prekallikrein deficiency in man